Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Flaherty

Showing results (381-390 of 580) with videos related to

Pageof 58
Sort By:
Cancer Cell|March 16, 2016
Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma TherapyMichael P Smith, Holly Brunton, Emily J Rowling, et al.
Oncoimmunology|May 4, 2018
A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanomaMeghan J Mooradian, Alexandre Reuben, Peter A Prieto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 28, 2023
Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of <i>BRAF</i>-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS TrialPaolo A Ascierto, Reinhard Dummer, Helen J Gogas, et al.
Cancer Discovery|February 3, 2019
MAPK Pathway Suppression Unmasks Latent DNA Repair Defects and Confers a Chemical Synthetic Vulnerability in <i>BRAF-, NRAS</i>-, and <i>NF1</i>-Mutant MelanomasOphélia Maertens, Ryan Kuzmickas, Haley E Manchester, et al.
Science Advances|November 14, 2020
Plasma-derived extracellular vesicle analysis and deconvolution enable prediction and tracking of melanoma checkpoint blockade outcomeAlvin Shi, Gyulnara G Kasumova, William A Michaud, et al.
European Journal of Cancer (Oxford, England : 1990)|March 18, 2020
Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019Selma Ugurel, Joachim Röhmel, Paolo A Ascierto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2019
Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based ValidationAndres F Correa, Opeyemi Jegede, Naomi B Haas, et al.
The Lancet. Oncology|February 15, 2021
Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation studyMahrukh M Syeda, Jennifer M Wiggins, Broderick C Corless, et al.
Cancer|October 11, 2013
Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients with advanced cancerChristine A Ciunci, Rodolfo F Perini, Anjali N Avadhani, et al.
The Lancet. Oncology|February 4, 2014
Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trialsKeith T Flaherty, Michael Hennig, Sandra J Lee, et al.
Pageof 58

Showing results (381-390 of 580) with videos related to

Sort By:
Pageof 58
Cancer Cell|March 16, 2016
Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma TherapyMichael P Smith, Holly Brunton, Emily J Rowling, et al.
Oncoimmunology|May 4, 2018
A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanomaMeghan J Mooradian, Alexandre Reuben, Peter A Prieto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 28, 2023
Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of <i>BRAF</i>-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS TrialPaolo A Ascierto, Reinhard Dummer, Helen J Gogas, et al.
Cancer Discovery|February 3, 2019
MAPK Pathway Suppression Unmasks Latent DNA Repair Defects and Confers a Chemical Synthetic Vulnerability in <i>BRAF-, NRAS</i>-, and <i>NF1</i>-Mutant MelanomasOphélia Maertens, Ryan Kuzmickas, Haley E Manchester, et al.
Science Advances|November 14, 2020
Plasma-derived extracellular vesicle analysis and deconvolution enable prediction and tracking of melanoma checkpoint blockade outcomeAlvin Shi, Gyulnara G Kasumova, William A Michaud, et al.
European Journal of Cancer (Oxford, England : 1990)|March 18, 2020
Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019Selma Ugurel, Joachim Röhmel, Paolo A Ascierto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2019
Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based ValidationAndres F Correa, Opeyemi Jegede, Naomi B Haas, et al.
The Lancet. Oncology|February 15, 2021
Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation studyMahrukh M Syeda, Jennifer M Wiggins, Broderick C Corless, et al.
Cancer|October 11, 2013
Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients with advanced cancerChristine A Ciunci, Rodolfo F Perini, Anjali N Avadhani, et al.
The Lancet. Oncology|February 4, 2014
Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trialsKeith T Flaherty, Michael Hennig, Sandra J Lee, et al.
Pageof 58